Central Trust Company’s Royalty Pharma RPRX Stock Holding History

Central Trust Company’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$785	Sell	14 -228	-94%	-$11.9K	﹤0.01%	1504
2026 Q1	$11.6K	Buy	242 +228	+1,629%	+$9.99K	﹤0.01%	1120
2025 Q4	$541	Hold	14	–	–	﹤0.01%	1435
2025 Q3	$494	Buy	+14	New	+$507	﹤0.01%	1366
2024 Q4	–	Sell	-3	Closed	-$85	–	1496
2024 Q3	$85	Buy	+3	New	+$83	﹤0.01%	1417

Other funds holding RPRX

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

WCM

Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return

Daiwa Securities Group Tokyo, Japan $51.1B AUM 35.55% 1-Year Est. Return

Eastern Bank Boston, Massachusetts $6.53B AUM 30.05% 1-Year Est. Return

TIP

Torray Investment Partners Bethesda, Maryland $741M AUM 26.16% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Calamos Advisors Naperville, Illinois $30.1B AUM 30.03% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

Central Trust Company's RPRX Position: Q2 2026 in Review

Central Trust Company reduced its Royalty Pharma (RPRX) stake by 94% in Q2 2026, selling an estimated $11.9K and leaving 14 shares worth $785. The position accounts for ﹤0.01% of the portfolio, ranked #1504.

Central Trust Company first reported a position in RPRX in Q3 2024 and has held it in 5 quarters since. The position peaked at $11.6K in Q1 2026. 208 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

Central Trust Company held 14 shares of Royalty Pharma worth $785 as of Q2 2026.
Central Trust Company sold 228 Royalty Pharma shares in Q2 2026, an estimated $11.9K.
Royalty Pharma made up ﹤0.01% of Central Trust Company's portfolio in Q2 2026, its #1504 holding.
Central Trust Company first reported a position in Royalty Pharma in Q3 2024 and has held it in 5 quarters since.
Central Trust Company's Royalty Pharma position peaked at $11.6K in Q1 2026.
208 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Central Trust Company's 13F filing for Q2 2026, filed 31 Jul 2026.